Table 2.
Estimated cost inputs used in the model
| Cost input | Value | |
|---|---|---|
| Cost administration and health States | ||
| PFS per course | ||
| Sorafenib | SBRT | |
| Drug or treatment cost | 537,264 | 210,000 |
| Costs of test: laboratory test, CT | 21,000 | 32,347 |
| Costs of physician visit, dispensing fee, nursing care | 3000 | 0 |
| Adverse events treatment | 38 | 16709 |
| Sub-total | 563,365 | 259,056 |
| PD per visit | ||
| Costs of test: laboratory test, CT | 10,728 | 10,728 |
| Costs of physician visit, dispensing fee, nursing care | 15,600 | 15,600 |
| End of life care | 391,200 | 391,200 |
| Sub-total | 417,528 | 417,528 |
Abbreviation: PFS progression free survival, PD progression disease, CT computerized tomography, SBRT stereotactic body radiotherapy